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REPLY
We thank Drs. Taylor-Robinson and Thomas for their interest in
our study, which found circulating Chlamydia pneumoniae (C.
pneumoniae) DNA to be associated with coronary artery disease
(CAD) in men but not women (1). The association in men was
moderate, with an odds ratio of 3.2 (95% confidence interval 1.1 to
8.9), and this was stronger than that reported in most serologic
studies (2). We discussed possible reasons for the lack of an
association in women, but because the number of male subjects was
over twice that of females, the statistical power to detect a
difference was strongest for men. In our study, patients and control
subjects were defined according to the presence of CAD by
angiographic criteria, an approach taken by other studies of C.
pneumoniae and CAD (2), and, indeed, by studies that have
investigated other coronary risk factors. We can justifiably claim
that we have found an association between C. pneumoniae DNA
and clinically significant atherosclerosis.
Our study and that of Boman et al. (3) are still the only
published reports on circulating C. pneumoniae DNA and CAD,
and we pointed out the differences in the reported prevalence of C.
pneumoniae DNA. In our view, the finding that circulating C.
pneumoniae DNA was found in 46% of a healthy, blood-donating
population (3) is remarkable and an extraordinarily high level for
any bacterium. However, although our study was far larger than
Boman’s, further work is required to clarify the situation, but we
cannot comment on the unpublished data of the correspondents or
their observations.
It would be generally accepted that evidence of current C.
pneumoniae infection should be found before prescribing antibiot-
ics to patients with CAD. At present, the presence of circulating
C. pneumoniae DNA is the most accurate method of diagnosing
current infection and is therefore a means of identifying suitable
patients for intervention trials. This was also a view held by the
correspondents (4), and we are therefore surprised by their state-
ment that “fortunately,” current antibiotic trials are being under-
taken with complete disregard for the PBMC C. pneumoniae
status. Fortunately, investigators running such trials do realize the
potential importance of such a test (5).
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The Electric Cardiographic
Abnormalities Are Not Hidden!
The report by Matetzky et al. (1) stimulates the following
thoughts. There are two ways to interpret electrocardiograms
(ECGs). One is to memorize patterns and the other is to use basic
principles of electrocardiography, including the use of vector
concepts, as described by Grant (2–6).
The tracing in Figure 1A of the report by Matetzky et al. reveals
a left atrial abnormality; a mean spatial QRS vector that is directed
at about 120° in the frontal plane (it changes direction during
inspiration and expiration) and about 45° posteriorly; a mean
spatial ST segment vector that is directed at 1115° in the frontal
plane and at least 90° posteriorly, indicating epicardial injury of the
posterior wall of the left ventricle; a mean spatial T-wave vector
that is directed at 190° in the frontal plane and 80° to 90°
anteriorly, indicating posterior myocardial ischemia; and a large U
wave in lead I.
The point is, the ST segment vector points toward an area of
posterior epicardial injury. Furthermore, one can suspect that the
ST segment vector is directed toward an obstruction in the
circumflex coronary artery or its branches. It should be no surprise
that the ST segment is elevated in leads V7–9, because the
transitional pathway was just beyond electrode position V6. The ST
segment abnormality is not hidden.
The follow-up discharge tracing in Figure 1B is also interesting.
The left atrial abnormality has disappeared; an S1, S2 and S3
conduction defect has developed; and the first half of the QRS
complex is directed at about 140° in the frontal plane and
markedly anterior, producing large abnormal R waves in leads V1
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and V2. This abnormality is due to a true posterior infarction.
Electrodes located anywhere on the front half of the chest would
record large R waves, and electrodes located anywhere on the back
half of the chest would record Q waves. The abnormal initial
portion of the QRS is not hidden.
The ECG shown in Figure 2 also reveals an S1, S2 and S3
conduction defect and abnormal ST segment displacement. Some
would argue that the ST segment displacement in the extremity
leads is an artifact due to downsloping of the recording. If that is
true, the mean ST segment vector points toward epicardial injury
surrounding a true posterior infarction, which is usually caused by
obstruction of the circumflex coronary artery, the distal right
coronary artery, or their branches. If the ST segment displacement
in the extremity leads is real, the mean ST segment vector is
directed at 30° to 60° in the frontal plane and about 45° posteriorly,
indicating epicardial injury of the left lateral and posterior portion
of the left ventricle. This could be caused by obstruction in the
obtuse marginal branch of the circumflex coronary artery or a
diagonal branch of the left anterior descending coronary artery.
The ST segment abnormality is not hidden.
None of the abnormalities are hidden, and true posterior
infarction should be considered in both of the 12-lead tracings.
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REPLY
In our article, we describe the clinical course, echocardiographic
and angiographic findings of 33 consecutive patients with acute
myocardial infarction and ST segment elevation in posterior chest
leads V7–9 but without significant ST segment elevation on the
standard 12-lead ECG. Because these ST segment elevations are
not presented on the classically performed 12-lead ECG, we called
them “hidden” (in quotation marks).
Like Dr. Hurst, who taught all of us through his textbook, we
were also much inspired by the vectorcardiographic approach to
electrocardiography so beautifully presented in Grant’s book (1).
However, the chest with the lungs full of air is not an ideal volume
conductor, and the heart is not in the exact middle of it. Most of
the time, whenever there is ST segment elevation in leads V7–9, ST
segment depression will be detected in the anterior chest leads.
However, there will always be cases, as we show here, where the
nonuniformity of the chest and other factors will result in distorted
spread of potential, leading to the absence of reciprocal changes in
leads V1–3, despite QRS–ST-T segment changes in leads V7–9.
We fully agree with the general statement by Dr. Hurst that
there are two ways to interpret the ECG: one is to memorize
patterns and the other is to use basic principles of electrocardiog-
raphy. But they are not mutually exclusive, and sometimes the
principles of volume conduction and nonuniformity and distorted
spread of potential will result in the changes we presented.
The posterior chest leads V7–9 ECG recording is simple and
feasible, and the appearance of ST segment elevations in posterior
chest leads V7–9 can be detected easily by any physician, even
without a deep understanding of basic ECG principles.
We believe that the early detection of ST segment elevation
posterior myocardial infarction in the era of reperfusion is crucial
for the identification of patients with acute posterior myocardial
infarction, who may benefit from reperfusion therapy.
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